MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

The best solutions provider for Alzheimer’s disease: TauRx Pharmaceuticals

The Silicon Review
November, 2018

thesiliconreview-claude-wischik-cofounder-chairman-taurx-pharmaceuticals-2018Innovation in neurodegeneration

Alzheimers disease is a progressive intellectual deterioration that may arise in center or antique age, due to generalized degeneration of the brain. it is the commonest cause of untimely senility. that is one of the developing troubles in todays era and it is because of this TauRx needed to come in the market. it's far now a pacesetter in Alzheimers disorder studies, TauRxs venture is to discover, broaden and commercialise innovative products for the prognosis, remedy and treatment of neurodegenerative diseases as a result of protein aggregation.

From initial discovery thru preclinical development to scientific trials, regulatory submission and product registration, we are harnessing international-class proprietary drug discovery platforms with the intention of halting the progression of Alzheimers and different neurodegenerative diseases with innovative remedies and diagnostics.

The agencys novel tau aggregation inhibitors (TAIs) goal the formation (aggregation) of tau protein tangles within the brain. The unfold of tau tangles the main driver in Alzheimers sickness is strongly correlated with dementia and they could broaden inside the mind up to twenty years before signs related to dementia develop. TAIs work through dissolving current tau aggregates and stopping the in addition aggregation of tau protein from forming new tangles.

The Company’s Speciality

The lead compound, LMTX®, inhibits aggregation of tau, synuclein, TPD-43 and huntingtin proteins. Patented as a novel chemical entity and chemically distinct from TauRx’s initial research compound, rember®, LMTX® has shown promise for slowing disease progression in Alzheimer’s disease and behavioural variant frontotemporal dementia.

Three LMTX® segment 3 medical trials, performed in over 20 countries and involving over 1,900 sufferers, have currently completed. Following those segment 3 trials, TauRx has started out a new medical trial, named LUCIDITY.

TauRx’s second-generation tau aggregation inhibitor (TAI), LMTX®, is a singular chemical shape of methylthioninium (MT). In its chloride salt form (methylene blue, or methylthioninium chloride (MTC)) it is an active moiety with a long records of use within the treatment of a selection of situations.

LMTX® works by undoing the tangles that cause dementia, thereby slowing and even arresting memory loss. This second-generation investigational drug has improved bioavailability, tolerability and safety compared with its predecessor, rember®, which was used in Phase 2 clinical trials in Alzheimer’s.

TauRx has a composition of count number patents and use patents masking the utility of its TAIs for the treatment and prevention of Alzheimers and FTD. The employer is likewise exploring the usage of TAIs in several other neurodegenerative sicknesses related to tau pathology, as well as different issues deriving from the aggregation of different proteins inside the brain, such as Parkinsons and Huntington’s.

How It All Began

more than decades ago, Professor Claude Wischik, a Professor of Psychiatric Geratology on the university of Aberdeen, and his team of bioscientists pioneered the early-degree research into tau aggregation inhibitors (TAIs) to particularly slow and halt the development of Alzheimers disease. With the effects of this foundational research showing promise, TauRx become based to preserve the work toward the development of an powerful treatment for the sickness and stays carefully linked to the university of Aberdeen to nowadays. A privately held enterprise, TauRxs robust studies team has been hooked up via cooperative relationships with multiple academic establishments round the world and has controlled to thrive innovatively while handing over valuable results in a brand new technology of medicine.

Having pioneered a new pathway to treat Alzheimer’s disease, TauRx presented the results of a large Phase 2 clinical trial involving 321 patients with mild and moderate Alzheimer’s in 2008. This study was conducted in the UK and Singapore and involved TauRx’s first-generation TAI, rember®. The results were reported at the Alzheimer’s Association International Conference on Alzheimer's Disease in Chicago, the USA in the same year and showed that the rate of Alzheimer’s progression was reduced by 90% over a 2-year period.

These findings were examined in section three medical trials, now completed, with the business enterprises 2nd-generation TAI, LMTX. The scientific trial programme involved over 1,900 sufferers and comprised three separate trials: in Alzheimer's disease and one inside the rare neurodegenerative disorder, behavioural variation frontotemporal dementia.

The Brains behind the Operations 

Prof. Claude Wischik - Co-Founder, Chairman and Chief Executive

Professor Wischik is board-certified in psychiatry and a professor of vintage Age Psychiatry at the university of Aberdeen, Scotland. A pioneer in Tau studies, he determined the tau protein compositional structure of the Alzheimers tangles and established that it become feasible to dissolve tangles with pharmaceutically possible compounds that act as Tau Aggregation Inhibitors.

“Taurx exists to solve and beat the world’s biggest challenges – Alzheimer disease and other degenerative brain diseases via a completely new approach.”

YOU MAY ALSO LIKE

Pine Labs Reaffirms its Commitment to Indian Payments Space with Qfix Acquisition

HDFC bank is Qfix's primary distribution partner Pine Labs has introduced that it has acquired Qfix, a Mumbai-based online payments startup. This acquisi...

Salesforce Expands into Thailand, Opens Office in Bangkok

Salesforce has introduced permanent presence in Thailand by using launching its new workplace in the u . s .s capital, Bangkok. The everlasting presence wi...

GMLL is expected to soon add two more stores to its retail arm ‘Price Mantra’

Garment Mantra lifestyle, a popular call inside the Indian fashion retail section, currently made an assertion that the organisation is expanding its retail ...

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The continued Covid pandemic had notably increased the variety of cell and net users global. The excessive amount of usage is expected to drop...

RECOMMENDED